Archive

Corporate news to the archive Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures Revenue and earnings up due to organic growth and successful acquisitions Vaccine production to commence in May 2021 ...

Corporate news to the archive Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021 Grünwald, February 12, 2021 - Dermapharm Holding ...

Corporate news to the archive Dermapharm Holding SE continues on its growth course in third quarter of 2020 Group revenue rose by 11.5% to EUR 577.2 million Adjusted Group EBITDA increased by 4.4% to EUR 139.0 million; corresponding ...

Corporate news to the archive Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine Grünwald, September 10, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer ...

Corporate News back to archive Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic Group revenue up 14% year-on-year to EUR 378 million Adjusted EBITDA of EUR 92 million around 2% ...

Corporate news to the archive Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share Annual General Meeting successfully held virtually Management Board and Supervisory Board discharged by a large ...

Corporate news to the archive Dermapharm confirms profitable growth in 2019 and presents positive outlook for 2020 despite corona Significant revenue and earnings growth in 2019 resulted from continuous product development, ...

Corporate news to the archive Dermapharm successfully acquires Allergopharma   Grünwald, March 31, 2020 - Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected ...

Corporate news to the archive Dermapharm continues its profitable growth in 2019 »          Group revenue of EUR 701 million in 2019, around 23% higher than in the previous year »          Adjusted EBITDA increases by approx. 24% ...

Grünwald, February 05, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, opened the new logistics center of its subsidiary mibe GmbH Arzneimittel in Brehna near Leipzig at the turn of the year.

Grünwald, 20 November 2019 – Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first nine months of 2019 today.

Grünwald, 12 September 2019 ‒ Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its half-year financial report for the first six months of 2019 today.

Corporate news to the archive Dermapharm continues on its profitable growth course in first half of 2019 Revenue up 19% year-on-year to EUR 333 million Adjusted EBITDA of EUR 90 million around 27% above previous ...

Grünwald, July 29, 2019 – The Supervisory Board of Dermapharm Holding SE (“Dermapharm”) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. Jürgen Ott to succeed him as of October 1, 2019.

Grünwald, July 1, 2019 – Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft ("Themis") that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.

Management Board and Supervisory Board discharged by large majority Fiscal year 2018 marked by introduction of self-developed products, further internationalization and successful acquisitions Continuation of profitable growth course in 2019

Grünwald, May 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its report for the first three months of 2019 today, having increased its revenues by 19.0% to EUR 163.6 million (prior-year quarter: EUR 137.5 million). Earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off costs of EUR 2.9 million in connection with the acquisition of the Spanish company Euromed and one-off costs of EUR 0.1 million for consulting services in connection with further acquisition efforts, increased by 20.7% to EUR 43.7 million (prior-year quarter: EUR 36.2 million). The adjusted EBITDA margin was 26.7%, 0.4 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 40.7 million while the unadjusted EBITDA margin was 24.9%.

Grünwald, April 17, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, today published its complete Annual Report 2018, confirming the preliminary IFRS Group financial figures for the year and the positive business development with significant revenue growth and a further increase in profitability.

Corporate news to the archive Dermapharm continues its profitable growth in 2018 Group revenue of EUR 572 million in 2018 around 23% higher than the previous year Adjusted EBITDA increases by approx. 27% compared to last ...

Corporate news to the archive Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications Grünwald, March 4, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded ...

Grünwald, February 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil® and Momekort® in Germany just in time for the hay fever season. In addition, the patented medical product bite away® from the 2018 Hyperthermia range has performed well in all sales channels.

Grünwald, January 23, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, is continuing its expansion course at the beginning of the year. The acquisition of the Spanish company EUROMED S.A. was completed at the beginning of January 2019.

Corporate News to the archive Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A. Grünwald, November 18, 2018 - Dermapharm Holding SE (ISIN: DE000A2GS5D8), a leading manufacturer of ...

Corporate news to the archive Dermapharm takes legal action against approval of a competitor product Grünwald, November 16, 2018 - Dermapharm Holding SE (WKN A2GS5D, ISIN DE000A2GS5D8), a leading manufacturer of ...

Corporate news to the archive Dermapharm Holding SE publishes report for first half of 2018 Group revenues increased by 19.7% to EUR 280.3 million Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin ...

Corporate news to the archive Dermapharm continues profitable growth in first half of 2018 Group revenues increased by around 20% from last year to EUR 280.3 million Adjusted EBITDA increased by around 30% over ...

Corporate news to the archive Dermapharm Holding SE: First Annual General Meeting after successful IPO   Grünwald, June 26, 2018 – Dermapharm Holding SE (WKN A2GS5D, ISIN (DE000A2GS5D8), a leading producer of ...

Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to ...

Corporate news to the archiv   Dermapharm plans further profitable growth in 2018 Sales and earnings growth in 2017 resulted from a successful strategy with a focus on select therapy fields Both segments ...

Corporate news to the archive Dermapharm continued profitable growth in 2017 Revenue in 2017 up 4.9% from last year to EUR 467 million Adjusted EBITDA up 9.7% from last year to EUR 113 million » Adjusted EBITDA ...

Corporate news to the archive   Not for release, publication or distribution in the United States, Canada, Australia or Japan. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, ...

Corporate news to the archive Not for release, publication or distribution in the United States, Australia, Canada or Japan. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, ...

Corporate news to the archive   Not for release, publication or distribution in the United States, Canada, Australia or Japan. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, ...